Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Signs Agreement for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease

BEVERLY, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, has signed an agreement with BDD Pharma, an...
May 29, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6

BEVERLY, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company will be...
May 21, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals At Digestive Disease Week Conference, Nears Selecting Drug Formulation Company to Prepare Oral Brilacidin for Targeted Delivery in Ulcerative Colitis

BEVERLY, Mass., May 21, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the...
May 16, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Announces Non-Binding Term Sheet Signed with Global Pharmaceutical Company to Develop and Commercialize Brilacidin for the Treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis

BEVERLY, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has signed...
May 01, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Receives FDA End-of-Phase 2 Meeting Minutes

BEVERLY, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today it has received Food and Drug...
April 23, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals - "JAMA" Article Reinforces Need for Novel Oral Mucositis Treatments in Supportive Cancer Care; Company progresses through first stage of review by European Medicines Agency (EMA) regarding Scientific Advice for planned Phase 3 Program

BEVERLY, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of a recent...
April 16, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Reports p53 Drug Candidate Therapeutic Potential Further Supported by Academic Research in Leukemias and in Combination with Cancer Immunotherapies

BEVERLY, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report recent academic and...
April 09, 2019 08:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Reports Enhancements in Manufacture of Brilacidin Phase 3 Drug Supply

BEVERLY, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has...
March 28, 2019 08:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals European Subsidiary, IPIX Pharma Ltd., Granted Meeting with European Medicines Agency (EMA) to Discuss International Phase 3 Brilacidin Oral Mucositis Program

BEVERLY, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the European Medicines...
March 15, 2019 08:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Requesting European Medicines Agency (EMA) Input for International Phase 3 Brilacidin Oral Mucositis Program

BEVERLY, Mass., March 15, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right